Compare NPK & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPK | SLS |
|---|---|---|
| Founded | 1905 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 945.9M | 924.5M |
| IPO Year | 1994 | 2007 |
| Metric | NPK | SLS |
|---|---|---|
| Price | $125.90 | $9.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 111.2K | ★ 7.8M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $503,524,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $110.98 |
| P/E Ratio | $129.38 | ★ N/A |
| Revenue Growth | ★ 29.70 | N/A |
| 52 Week Low | $91.28 | $1.39 |
| 52 Week High | $149.86 | $9.51 |
| Indicator | NPK | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 40.36 | 62.82 |
| Support Level | $123.35 | $3.72 |
| Resistance Level | $147.26 | $9.51 |
| Average True Range (ATR) | 4.40 | 0.66 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 18.10 | 89.45 |
National Presto Industries Inc has an electric product portfolio consisting of household appliances, ammunition, and diapers. The company operates in three segments, namely Defense, Housewares/Small Appliance, and Safety. The defense segment, which is engaged in manufacturing 40mm ammunition, precision mechanical and electro-mechanical assemblies, and medium caliber cartridge cases, performs Load, Assemble, and Pack (LAP) operations on ordnance-related products for the U.S. Government and prime contractor. While the Housewares/Small Appliance segment designs, markets, and distributes housewares and small electrical appliances, the safety segment provides safety technology empowering organizations and individuals to protect what is more important.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.